Preventive medicine for HIV-infected patients - An analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patients

David N. Rose, Clyde B. Schechter, Henry S. Sacks

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective:To analyze the policies of isoniazid prophylaxis for human immunodeficiency virus (HIV)-infected tuberculin reactors and for HIV-infected anergic patients with unknown tuberculin status. Methods:Transition-state model of clinical immune deterioration of HIV-infection over ten years, review of published data, and a survey of AIDS experts. Outcome measures are the numbers of tuberculosis cases and deaths prevented and isoniazid toxicity cases and deaths occurring with prophylaxis. Patients:Hypothetical cohorts of HIV-infected 40-year-olds. Results:Because the tuberculosis activation rate is so high in HIV-infected patients, the benefits of prophylaxis far outweigh the risks of isoniazid toxicity for tuberculin reactors with HIV infection at any stage of immune function: 1,469-2,868 tuberculosis cases and 170-274 deaths are prevented per 10,000 cohort over ten years, depending upon the cohort's initial immune state. The benefits of prophylaxis outweigh the risks of isoniazid toxicity for anergic HIV-infected patients if they come from a community with a 2% to 3% or greater prevalence of Mycobacterium tuberculosis infection. Conclusions:Isoniazid prophylaxis is a reasonable prevention measure for HIV-infected tuberculin reactors and for many HIV-infected anergic patients.

Original languageEnglish (US)
Pages (from-to)589-594
Number of pages6
JournalJournal of General Internal Medicine
Volume7
Issue number6
DOIs
StatePublished - Nov 1992
Externally publishedYes

Fingerprint

Preventive Medicine
Tuberculin
Isoniazid
HIV
Tuberculosis
Virus Diseases
Mycobacterium Infections
Policy Making
Mycobacterium tuberculosis
Acquired Immunodeficiency Syndrome
Outcome Assessment (Health Care)

Keywords

  • AIDS
  • HIV
  • isoniazid
  • prevention
  • tuberculosis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Preventive medicine for HIV-infected patients - An analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patients. / Rose, David N.; Schechter, Clyde B.; Sacks, Henry S.

In: Journal of General Internal Medicine, Vol. 7, No. 6, 11.1992, p. 589-594.

Research output: Contribution to journalArticle

@article{6bb6240399e647cab2eff1158173318d,
title = "Preventive medicine for HIV-infected patients - An analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patients",
abstract = "Objective:To analyze the policies of isoniazid prophylaxis for human immunodeficiency virus (HIV)-infected tuberculin reactors and for HIV-infected anergic patients with unknown tuberculin status. Methods:Transition-state model of clinical immune deterioration of HIV-infection over ten years, review of published data, and a survey of AIDS experts. Outcome measures are the numbers of tuberculosis cases and deaths prevented and isoniazid toxicity cases and deaths occurring with prophylaxis. Patients:Hypothetical cohorts of HIV-infected 40-year-olds. Results:Because the tuberculosis activation rate is so high in HIV-infected patients, the benefits of prophylaxis far outweigh the risks of isoniazid toxicity for tuberculin reactors with HIV infection at any stage of immune function: 1,469-2,868 tuberculosis cases and 170-274 deaths are prevented per 10,000 cohort over ten years, depending upon the cohort's initial immune state. The benefits of prophylaxis outweigh the risks of isoniazid toxicity for anergic HIV-infected patients if they come from a community with a 2{\%} to 3{\%} or greater prevalence of Mycobacterium tuberculosis infection. Conclusions:Isoniazid prophylaxis is a reasonable prevention measure for HIV-infected tuberculin reactors and for many HIV-infected anergic patients.",
keywords = "AIDS, HIV, isoniazid, prevention, tuberculosis",
author = "Rose, {David N.} and Schechter, {Clyde B.} and Sacks, {Henry S.}",
year = "1992",
month = "11",
doi = "10.1007/BF02599196",
language = "English (US)",
volume = "7",
pages = "589--594",
journal = "Journal of General Internal Medicine",
issn = "0884-8734",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Preventive medicine for HIV-infected patients - An analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patients

AU - Rose, David N.

AU - Schechter, Clyde B.

AU - Sacks, Henry S.

PY - 1992/11

Y1 - 1992/11

N2 - Objective:To analyze the policies of isoniazid prophylaxis for human immunodeficiency virus (HIV)-infected tuberculin reactors and for HIV-infected anergic patients with unknown tuberculin status. Methods:Transition-state model of clinical immune deterioration of HIV-infection over ten years, review of published data, and a survey of AIDS experts. Outcome measures are the numbers of tuberculosis cases and deaths prevented and isoniazid toxicity cases and deaths occurring with prophylaxis. Patients:Hypothetical cohorts of HIV-infected 40-year-olds. Results:Because the tuberculosis activation rate is so high in HIV-infected patients, the benefits of prophylaxis far outweigh the risks of isoniazid toxicity for tuberculin reactors with HIV infection at any stage of immune function: 1,469-2,868 tuberculosis cases and 170-274 deaths are prevented per 10,000 cohort over ten years, depending upon the cohort's initial immune state. The benefits of prophylaxis outweigh the risks of isoniazid toxicity for anergic HIV-infected patients if they come from a community with a 2% to 3% or greater prevalence of Mycobacterium tuberculosis infection. Conclusions:Isoniazid prophylaxis is a reasonable prevention measure for HIV-infected tuberculin reactors and for many HIV-infected anergic patients.

AB - Objective:To analyze the policies of isoniazid prophylaxis for human immunodeficiency virus (HIV)-infected tuberculin reactors and for HIV-infected anergic patients with unknown tuberculin status. Methods:Transition-state model of clinical immune deterioration of HIV-infection over ten years, review of published data, and a survey of AIDS experts. Outcome measures are the numbers of tuberculosis cases and deaths prevented and isoniazid toxicity cases and deaths occurring with prophylaxis. Patients:Hypothetical cohorts of HIV-infected 40-year-olds. Results:Because the tuberculosis activation rate is so high in HIV-infected patients, the benefits of prophylaxis far outweigh the risks of isoniazid toxicity for tuberculin reactors with HIV infection at any stage of immune function: 1,469-2,868 tuberculosis cases and 170-274 deaths are prevented per 10,000 cohort over ten years, depending upon the cohort's initial immune state. The benefits of prophylaxis outweigh the risks of isoniazid toxicity for anergic HIV-infected patients if they come from a community with a 2% to 3% or greater prevalence of Mycobacterium tuberculosis infection. Conclusions:Isoniazid prophylaxis is a reasonable prevention measure for HIV-infected tuberculin reactors and for many HIV-infected anergic patients.

KW - AIDS

KW - HIV

KW - isoniazid

KW - prevention

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=0026591840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026591840&partnerID=8YFLogxK

U2 - 10.1007/BF02599196

DO - 10.1007/BF02599196

M3 - Article

C2 - 1360493

AN - SCOPUS:0026591840

VL - 7

SP - 589

EP - 594

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

SN - 0884-8734

IS - 6

ER -